درباره این اپیزود
John Zutter took over as CEO of Lantern in December 2016 — right after the company lost 50% of its clients in six months. Today, Lantern is one of the largest specialty care platforms in the country, serving 12 million people across 500+ facilities, with a surgical complication rate under 1% (vs. a national average of 8-15%).
In this episode, we go deep on how Lantern rebuilt trust with employers, why the "fly patients to a name-brand hospital" model failed, the five-part heuristic Lantern uses to decide which conditions to tackle next, why they chose to open-source their savings methodology, and where AI actually moves the needle in specialty care versus where it doesn't.
John spent his early career in investment banking and growth equity before joining Lantern in 2016 with no healthcare background — and turned around a business now backed by a $30M round led by Morgan Health (JPMorgan Chase) and Echo Health Ventures.
In this episode:
- Why Lantern lost half its clients before John took over — and what was actually broken
- The "Centers of Excellence" model that looked good on paper but failed in practice
- How Lantern scaled a two-sided provider network market by market
- The real reason their complication rate is under 1%
- How Lantern decides which new categories to enter (surgery → cancer → infusions)
- Why they open-sourced their savings and bundling methodology — and why competitors haven't followed
- What CEOs, CFOs, and benefits leaders each actually want from a healthcare vendor
- Where AI will — and won't — change specialty care
- His non-consensus take on GLP-1s
Timestamps:
00:00 – Intro
01:11 – Coming into healthcare with no healthcare background
03:59 – Taking over Lantern after losing half its clients
05:58 – Why the "Centers of Excellence" model failed
08:06 – Scaling a two-sided provider network
12:11 – Advice for early-stage founders on network-based models
14:54 – How Lantern gets complication rates under 1%
17:07 – Addressing the "cherry-picking healthy patients" critique
20:12 – Why cancer, surgery, and infusions eat 50%+ of health spend
23:12 – Expanding from surgery into cancer care
26:22 – Partnerships vs. building in-house (Access Hope, Hinge Health)
28:20 – Expanding into infusion therapy
30:18 – When platform consolidation helps buyers — and when it doesn't
35:25 – Why Lantern open-sourced its savings methodology
39:45 – Where AI fits into the next 5 years of specialty care
44:55 – Shifting from procedural to therapeutic care (GLP-1s, cell/gene therapy)
46:38 – Working with health plans vs. employers directly
49:12 – A non-consensus bet on GLP-1s
50:09 – Rapid fire
More about John Zutter & Lantern
John's LinkedIn: https://www.linkedin.com/in/john-zutter-687000a/
Lantern's LinkedIn: https://www.linkedin.com/company/lantern-specialty-care/
Lantern's Website: https://lanterncare.com/
More about Vik & Care Shift
Vik's LinkedIn: https://www.linkedin.com/in/sathvik-bilakanti-8b5344169/
Care Shift LinkedIn: https://www.linkedin.com/company/care-shift/?viewAsMember=true
Care Shift Website: https://careshift.vc/
